The Journal of neuropsychiatry and clinical neurosciences · 2025
Association of Favorable Cerebrospinal Fluid Markers With Reversion of Mild Cognitive Impairment Due to Parkinson's Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ryczek Cameron A, Rivas Rhiannon, Hemphill Lea, Zanotelli Zackary, Renteria Nicholas, Dashtipour Khashayar, Jones Jacob D
Аннотация
OBJECTIVE: Cognitive impairment is a common nonmotor symptom among individuals with Parkinson's disease (PD). Although cognitive impairment generally develops progressively, individuals with PD-associated mild cognitive impairment (PD-MCI) may revert to being cognitively normal (CN), which is referred to as PD-MCI reversion. Previous studies are inconsistent in whether PD-MCI reverters are at greater risk for PD-MCI recurrence relative to CN individuals. Even less is known about how PD-MCI reverters compare with CN individuals or PD-MCI nonreverters in terms of neurodegenerative biomarkers. The authors examined group differences (CN, PD-MCI reversion, and PD-MCI nonreversion) in cerebrospinal fluid (CSF) markers of Alzheimer's disease (AD), including amyloid beta, tau (total [t-tau] and phosphorylated [p-tau]), and alpha-synuclein.
METHODS: Data from the longitudinal international multisite Parkinson Progression Marker Initiative were used. Participants were newly diagnosed as having PD (N=430) and completed a battery of neurocognitive assessments at baseline and annual follow-ups for up to 5 years. Participants were classified as CN, PD-MCI reverters, or PD-MCI nonreverters on the basis of the first two neurocognitive assessments.
RESULTS: The PD-MCI nonreversion group had greater p-tau:amyloid beta and t-tau:amyloid beta ratios relative to the PD-MCI reversion group. The CN and PD-MCI reversion groups did not significantly differ in any of the CSF markers.
CONCLUSIONS: PD-MCI reverters may have a more favorable trajectory in terms of AD pathology relative to PD-MCI nonreverters. Future studies are needed to verify whether PD-MCI reversion may represent an intermediate prognostic group between CN individuals and those with MCI nonreversion.
METHODS: Data from the longitudinal international multisite Parkinson Progression Marker Initiative were used. Participants were newly diagnosed as having PD (N=430) and completed a battery of neurocognitive assessments at baseline and annual follow-ups for up to 5 years. Participants were classified as CN, PD-MCI reverters, or PD-MCI nonreverters on the basis of the first two neurocognitive assessments.
RESULTS: The PD-MCI nonreversion group had greater p-tau:amyloid beta and t-tau:amyloid beta ratios relative to the PD-MCI reversion group. The CN and PD-MCI reversion groups did not significantly differ in any of the CSF markers.
CONCLUSIONS: PD-MCI reverters may have a more favorable trajectory in terms of AD pathology relative to PD-MCI nonreverters. Future studies are needed to verify whether PD-MCI reversion may represent an intermediate prognostic group between CN individuals and those with MCI nonreversion.